New hope for controlling debilitating nosebleeds in rare disease
Disease control
Ongoing
This study is testing whether a drug called pazopanib can help people with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder that causes frequent, severe nosebleeds and anemia. About 70 participants will take either pazopanib or a placebo pill daily for 24 weeks to …
Phase: PHASE2, PHASE3 • Sponsor: Cure HHT • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC